NK cell-triggered CCL5/IFNγ-CXCL9/10 axis underlies the clinical efficacy of neoadjuvant anti-HER2 antibodies in breast cancer

NK cell-triggered CCL5/IFNγ-CXCL9/10 axis underlies the clinical efficacy of neoadjuvant anti-HER2 antibodies in breast cancer

Abstract Background The variability in responses to neoadjuvant treatment with anti-HER2 antibodies prompts to personalized clinical management and the development of innovative treatment strategies. Tumor-infiltrating Natural Killer (TI-NK) cells can predict the efficacy of HER2-targeted antibodies...

Full description

Bibliographic Details
Main Authors: Sara Santana-Hernández, Jesús Suarez-Olmos, Sonia Servitja, Pau Berenguer-Molins, Marcel Costa-Garcia, Laura Comerma, Anna Rea, Julia Perera-Bel, Silvia Menendez, Oriol Arpí, Begoña Bermejo, María Teresa Martínez, Juan Miguel Cejalvo, Iñaki Comino-Méndez, Javier Pascual, Emilio Alba, Miguel López-Botet, Federico Rojo, Ana Rovira, Joan Albanell, Aura Muntasell
Format: Article
Language:English
Published: BMC 2024-01-01
Series:Journal of Experimental & Clinical Cancer Research
Subjects:
NK cells
Anti-HER2 antibodies
Biomarker
HER2 positive breast cancer
CCL5
IFN-ɣ
Online Access:https://doi.org/10.1186/s13046-023-02918-4

Internet

https://doi.org/10.1186/s13046-023-02918-4

Similar Items